New hope for older blood cancer patients: smarter transplants aim to cut relapse

NCT ID NCT04217278

Ongoing Disease control Sponsor: University of Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This clinical trial is testing different treatment strategies to improve outcomes for older adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are getting a stem cell transplant. The study compares a new pre-transplant drug (Vyxeos) with standard therapy, and also tests different conditioning regimens before transplant based on age. Around 333 participants are being followed for at least two years to see which approach works best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Vyxeos, Fludarabine, Busulphan, Thiotepa, Cytarabine
What this could lead to: If successful, this could lead to better survival and lower relapse rates for older adults with AML or high-risk MDS after stem cell transplant.
What could go wrong: This is a mid-stage trial with 333 participants, and results may not apply to all patients. Transplants carry serious side effects, and the new therapies might not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA HIGH RISK MYELODYSPLASTIC SYNDROME

Contacts and locations

Locations

Addenbrooke's Hospital

Cambridge, United Kingdom
Churchill Hospital

Oxford, United Kingdom
Derriford Hospital

Plymouth, United Kingdom
Freeman Hospital

Newcastle, United Kingdom
Hammersmith Hospital

London, United Kingdom
King's College Hospital

London, United Kingdom
Leicester Royal Infirmary

Leicester, United Kingdom
Manchester Royal Infirmary

Manchester, United Kingdom
Nottingham City Hospital

Nottingham, United Kingdom
Queen Elizabeth Hospital

Birmingham, United Kingdom
Queen Elizabeth Hospital Glasgow

Glasgow, United Kingdom
St James' University Hospital

Leeds, United Kingdom
University Hospital of Wales

Cardiff, United Kingdom
University Hospitals Bristol

Bristol, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.